

ARGENTUM PHARMACEUTICALS LLC, Petitioner

v.

MERCK PATENTGESELLSCHAFT, Patent Owner.

U.S. Patent No. 8,673,921
Issue Date: March 18, 2014
Title: POLYMORPHIC FORMS OF
1-[4-(5-CYANOINDOL-3-YL)BUTYL]-4(2-CARBAMOYLBENZOFURAN-5-YL)
PIPERAZINE HYDROCHLORIDE

Inter Partes Review No.: Unassigned

DECLARATION OF GABRIELA GURAU, PH.D.



I, Gabriela Gurau, Ph.D., do hereby declare and state as follows:

- 1. I am currently CEO and Co-owner of 525 Solutions, Inc. After receiving my Ph.D. degree in Chemistry from The University of Alabama, I accepted a position as a Postdoctoral Research Fellow at QUILL (Queen's University Ionic Liquid Laboratories) in Belfast, Northern Ireland, an industrial consortium with members from all sectors of the chemical industry. In 2009, I returned to Alabama where I held the positions of postdoc at The University of Alabama and Chief Technical Officer at 525 Solutions. In 2015, I accepted a position at McGill University, Montreal, Canada as an Academic Associate in Green Chemistry, managing the \$10M Canada Excellence Research Chair program. I returned to 525 Solutions in 2017.
- 2. I am being compensated for my work at a rate of \$150 per hour. My compensation is not dependent on and in no way affects the substance of my statements in this Declaration. I have no financial interest in the outcome of this proceeding.
- 3. I have personal knowledge of the experiments performed in the laboratory notebook pages marked as Exhibit 1034. I hereby declare that Exhibit 1034 is a true and correct copy of the laboratory notebook that I used when I performed the experiments under the supervision and direction of Dr. Robin D. Rogers, Ph.D. between October 23, 2017 and December 12, 2017.



Date: December 15, 2017

RESPECTFULLY SUBMITTED,

Gabriela Gurau, Ph.D.